Myriad Genetics ( (MYGN) ) has released its Q3 earnings. Here is a breakdown of the information Myriad Genetics presented to its investors.

Nov. 7, 2024 — Researchers have used ancient DNA to challenge long-held interpretations of the people of Pompeii. Contrary to physical appearances, the DNA evidence revealed unexpected ...

GeneSight, a Mason-based company specializing in mental health medication, expanded its wellness services in the community.

Investigation Details On October 31, 2024, it was revealed that UnitedHealth Group (“UnitedHealth”) would no longer cover GeneSight, Myriad’s genetic test to help determine which mental health ...

Highlights Third quarter revenue grew 11% year-over-year to $213 million, driven by Pharmacogenomics (34%) and Prenatal (10%) ...

Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy.

SALT LAKE CITY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, was ...

The catalogue of genetic factors that have been implicated in kidney disease continues to grow. In this guide to gene–disease relationships, the authors discuss the crucial process whereby ...

UnitedHealth (UNH) on Friday disclosed that it would stop covering multi-panel pharmacogenetic tests, including Myriad’s (MYGN) ...

Myriad Genetics stock plunges after UnitedHealth Group announces they will no longer cover genetic tests for mental health ...

As genetic testing becomes more available, patients are gaining unprecedented access to information about the likelihood of diseases and medical conditions. There is increased demand for professionals ...